Plain-English translation of NCT07070765 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Some breast cancer chemotherapy drugs, called anthracyclines, can damage the heart in about 1 out of 10 patients who receive them. This trial is testing whether a medication called dapagliflozin—which was originally developed for diabetes but may also help the heart—can protect your heart during and after this chemotherapy. Researchers believe the medication works by restoring energy to heart cells that are being damaged by the cancer drugs.
Heart damage from these cancer drugs is serious and hard to treat once it happens. This medication might prevent that damage from occurring in the first place, but researchers need to test whether it actually works and is safe for cancer patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the heart-protective medication or a placebo (dummy pill) in addition to your standard cancer chemotherapy. The study team will use a special heart scan (cardiac magnetic resonance spectroscopy) to measure your heart's energy levels before, during, and after your chemotherapy to see if the medication makes a difference. You will continue in the study for the duration of your chemotherapy treatment, typically several months.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United Kingdom